Developing a new treatment for bronchopulmonary dysplasia in infants
Official title: Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia
Funded at Reneurogen, LLC · NIH-11311467 · Data updated 2026-11-12
This study is working on a new medicine to help treat bronchopulmonary dysplasia (BPD) in premature babies, and the researchers are making sure it’s safe to test in humans so that it can eventually be available to those who need it.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Reneurogen, LLC NIH-funded |
| Lab location | 1 site (Elm Grove, United States) |
| Project start | June 15, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $50,000 |
| NIH project number | 3R44HL166018-02S1 |
| Project ID | NIH-11311467 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are premature infants diagnosed with bronchopulmonary dysplasia.
✕Less likely to help
Patients who are not premature or do not have bronchopulmonary dysplasia may not benefit from this research.
What this research studies
This research focuses on creating a novel drug candidate aimed at treating bronchopulmonary dysplasia (BPD), a serious lung condition affecting premature infants. The drug, known as N-acetyl-lysyltyrosylcysteine amide (KYC), has shown promising results in animal models. The research team is working on regulatory planning and engaging with the FDA to ensure the drug can be safely tested in humans. By collaborating with experts in pediatric drug development, the team aims to navigate the complexities of bringing this treatment to market.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for infants suffering from bronchopulmonary dysplasia, improving their lung health and overall quality of life.
How similar studies have gone: Previous research has shown success with similar pharmacological approaches in treating chronic lung diseases in infants, indicating potential for this novel treatment.
Where this research is happening
-
Reneurogen, LLC
Elm Grove, United States Active
Researchers
- Principal investigator: Naylor, Stephen — Reneurogen, LLC
- Study coordinator: Naylor, Stephen
Related research
Other NIH-funded projects on the same topics.
-
Role of uneven lung growth in chronic lung disease from birth to adulthood
This grant explores how mismatched growth of airways, airspaces, and blood vessels during early life might lead to lasting lung problems in bronchopulmonary dysplasia and how that affects people over time.
-
Regulatory T Cells and Lung Disease-Related High Blood Pressure in Adults
This project studies how a type of immune cell called regulatory T cells may influence inflammation and blood vessel changes in lung disease, with potential relevance to adults who have vascular issues in their lungs.
-
Understanding how breathing effort in premature babies with lung disease comes from different lung problems
A research project aims to create a patient-specific tool to measure how different features of bronchopulmonary dysplasia contribute to the struggle to breathe in premature infants.
-
Role of LKB1 in reduced lung blood vessel growth in BPD
Aims to understand how a cellular regulator (LKB1) affects blood vessel formation in the lungs of preterm infants at risk for bronchopulmonary dysplasia.
-
A new approach to prevent bronchopulmonary dysplasia in preterm infants
A new treatment strategy aimed at improving lung development in premature babies at risk for bronchopulmonary dysplasia.
-
L-Citrulline for BPD-related Pulmonary Hypertension in Preterm Babies
A first-in-human study will test safe and effective doses of L-citrulline given by mouth to stability-preterm infants at risk for lung blood pressure problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.